Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1

Conditions

Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Arsenic × Clear all
NCT06982274 2025-05-30

IC-APL2020

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
115 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04695223 2021-01-06

Arsenic Trioxide for Structural p53 Mutations

Shanghai Changzheng Hospital

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT03381781 2018-01-04

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Ruijin Hospital

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡